EP1003738A1 - Composes bicycliques servant de ligands pour les recepteurs 5-ht1 - Google Patents

Composes bicycliques servant de ligands pour les recepteurs 5-ht1

Info

Publication number
EP1003738A1
EP1003738A1 EP98946322A EP98946322A EP1003738A1 EP 1003738 A1 EP1003738 A1 EP 1003738A1 EP 98946322 A EP98946322 A EP 98946322A EP 98946322 A EP98946322 A EP 98946322A EP 1003738 A1 EP1003738 A1 EP 1003738A1
Authority
EP
European Patent Office
Prior art keywords
formula
pyridin
compound
nitrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98946322A
Other languages
German (de)
English (en)
Other versions
EP1003738B1 (fr
Inventor
Laramie M. SmithKline Beecham Pharma. GASTER
Paul A. SmithKline Beecham Pharma. WYMAN
Sean Thomas Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716804.1A external-priority patent/GB9716804D0/en
Priority claimed from GBGB9801633.0A external-priority patent/GB9801633D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1003738A1 publication Critical patent/EP1003738A1/fr
Application granted granted Critical
Publication of EP1003738B1 publication Critical patent/EP1003738B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds, processes for their preparation, and pharmaceutical compositions containing them.
  • EPA 0733628 discloses a series of indole derivatives which are said to possess
  • 5HTIF agonist activity 5HTIF agonist activity. These compounds are alleged to be of use in the treatment of migraine and associated disorders.
  • EPA 0533266/7/8 disclose a series of benzanilide derivatives which are said to possess 5-HTj ) receptor antagonist activity.
  • the 5-HTID receptor was subsequently found to consist of a pair of gene products originally designated 5-HTiD ⁇ and 5-HT ⁇ > ⁇ receptors which have more recently been reclassified as 5-HTID and 5-HTIJJ receptors, respectively. (Hartig, P.R. et al, Trends in Pharmacological Sciences 1992, Vol. 13, page 152, Hartig, P.R. et al., Trends in Pharmacological Sciences, 1996, Vol. 17, pagel03).
  • the present invention therefore provides a compound of formula (I) or a salt thereof:
  • R a is a group of formula (i)
  • pi is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • R 2 is hydrogen, halogen, Cj. ⁇ alkyl, C3_6cycloalkyl, C3_6cycloalkenyl, Ci.galkoxy,
  • COC ⁇ _6alkyl ar y ⁇ acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO 2 RlO,
  • P 2 and P ⁇ are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
  • A is a bond or oxygen, S(O) m where m is 0, 1 or 2, carbonyl, or CH 2 or NR ⁇ where R ⁇ is hydrogen or Cj.galkyl;
  • Rl is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C ⁇ .galkyl, halogen or Cj.g alkanoyl;
  • R2 and R ⁇ are as defined for R 2 in formula (i); and a and b are independently 1, 2 or 3;
  • L is a group of formula
  • V is oxygen or sulphur
  • D is nitrogen, carbon or a CH group
  • Y is -NH-or -NR ⁇ - and V is oxygen or sulphur; or (b) both Y and V are oxygen; or (c) Y is CH 2 and V is oxygen then pl is not phenyl within the definition of R a formula (i) and R a is not an unsubstituted biphenyl within the definition of formula (ii)
  • Q is an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
  • RY is a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • R D is hydrogen, halogen, hydroxy, Chalky., trifluoromethyl, Cj.galkoxy or aryl; or R D together with G forms a group W as defined above;
  • C ⁇ _6alkyl groups whether alone or as part of another group may be straight chain or branched.
  • the term 'acyloxy' is used herein to describe a group -OC(O)C ⁇ .galkyl.
  • the term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl.
  • the term 'aralkyl' is used herein to describe, unless otherwise stated, a group such as benzyl.
  • the bicyclic aryl group represented by pi, P 2 and/or P ⁇ , which may be partially saturated, is preferably naphthyl.
  • bicyclic heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur include quinoline, isoquinoline, indole, benzofuran and benzothiophene rings.
  • the heterocyclic groups can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.
  • Examples of 5 to 7 membered heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur represented by pi, P 2 and/or P ⁇ include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl and pyrazinyl, preferably pyridyl.
  • R! is preferably a halogen atom for example, fluorine, chlorine or bromine, and R2 and or R ⁇ are each preferably hydrogen, halogen for example a chloro group or a C ⁇ . galkyl group for example a methyl group.
  • a and b are each preferably 1 or 2.
  • A is preferably a bond.
  • V is preferably oxygen.
  • G D is preferably nitrogen and G is preferably a hydrogen atom or together with R D forms group- W, preferably -(CH 2 ) 2 -.
  • Rb is preferably hydrogen or R D together with G forms group W referred to above.
  • Q is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur.
  • Q is a 5- or 6-membered ring containing one or two heteroatoms.
  • Suitable optional substituents for the ring Q include groups R and R 2 as defined above, preferably C ⁇ alkyl, most preferably methyl.
  • the group RY can be fully or partially saturated and can be linked to the group Q via a carbon atom or, when present, a suitable nitrogen atom.
  • R v is 5 or 6 membered heterocyclic containing 1 or 2 nitrigen atoms.
  • RY is a piperidinyl group.
  • Particularly preferred compounds according to the invention include:- N-[3-(l-Methylpiperidin-4-yl)indol-5-yl]-N'-[4-(pyridin-4-yl)naphth-l-yl]-urea,
  • Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
  • acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
  • Y is -CH 2 - or -O- and ⁇ is an appropriate leaving group, with a compound of formula (III)
  • reaction in process (a) is conveniently effected in an organic solvent such as dichloromethane.
  • the urea forming agent can be carbonyl diimidazole, triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • the leaving group ⁇ 7 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • the leaving group ⁇ 7 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques.
  • Intermediate compounds of formula (II), (III), (IV), (V), (VI) and (VII) can be prepared using standard procedures known in the art.
  • Carboxylic acid groups can be protected as esters.
  • Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.
  • Serotonin (5-hydroxytryptamine; 5HT) receptors have been implicated in a number of pharmacological effects including mood disorders including depression, seasonal affective disorder and dysthymia, anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sleep disorders (including disturbances of Circadian rhythm), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
  • mood disorders including depression, seasonal affective disorder and dysthymia
  • anxiety disorders including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder
  • memory disorders including dementia, amnesic disorders and
  • Serotonin receptor ligands have been shown to be of use in the treatment of emesis and nausea and may also be of use in endocrine disorders such as hyperlactinaemia, vasospasm (particularly in the cerebral vasculature), cerebellar ataxia and hypertension, as well as disorders of the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia. Ligands with high affinity for the 5HTj receptors are well recognised as having therapeutic utility for the treatment of the the above conditions.
  • WO 95/31988 refers to the use of a 5-HTID receptor antagonist in co ⁇ juncton with a 5-HTIA receptor antagonist t ⁇ treat CNS, endocrine and GI disorders
  • K. Rasmussen Annual Reports in Medicinal Chemistry, (1995) 30, 1) describes the utility of 5-HT ⁇ A receptor agonists and partial agonists in the treatment of various CNS disorders
  • P. Trouillas Progress in Brain Research, C.I. de Zeeuw, P. Stara and J. Voogd, Eds. 1997, 144, 589)
  • G. Maura J. Neurochemistry, 1996, 6 ⁇ , 202 propose that administration of agonist ligands selective for the 5-HT ⁇ A receptor or for both 5-HT ⁇ A ⁇ d 5-HTID receptors should provide effective treatment for human cerebellar ataxias.
  • the present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
  • the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
  • the affinities of the compounds of this invention for the 5HTIA > 5-HT ⁇ and 5-HTID receptors can be determined by the following radioligand binding assay.
  • HEK 293 cells expressing 5-HT i A receptors (4 x 10 7 /ml) are homogenised in Tris buffer and stored in 1ml aliquots.
  • CHO cells expressing 5-HT j ⁇ receptors (4 x 10 7 cells/ml) are homogenised in Tris buffer and stored in 1.5 ml aliquots.
  • CHO cells expressing 5-HT ⁇ j) receptors (0.563 x 10 ⁇ /ml) are homogenised in Tris buffer and stored in 1 ml aliquots.
  • pKi values are calculated from the IC50 generated by an iterative least squares curve fitting programme.
  • the intrinsic activity of the compounds of this invention can be determined according to the following procedure. HEK293 cell membranes stably expressing human 5-HT i A receptors and CHO cell membranes stably expressing human 5-HTi g receptors are homogenised in HEPES/EDTA buffer and stored in 1ml aliquots, and [ 35 S]GTP ⁇ S binding studies are carried out essentially as described by Lazareno et al., (Life Sci., 1993, 52, 449) with some minor modifications.
  • Membranes from 10 ⁇ cells are pre- incubated at 30°C for 30 minutes in 20 mM HEPES buffer (pH 7.4) in the presence of MgCl 2 (3 mM), NaCl (100 mM), GDP (10 ⁇ M) and ascorbate (0.2 mM), with or without test compounds.
  • the reaction is started by the addition of 10 ⁇ l of [ 35 S]GTP ⁇ S (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C.
  • Non-specific binding is determined using nonradiolabelled GTP ⁇ S (20 ⁇ M) added prior to the membranes.
  • the reaction is terminated by rapid filtration through Whatman GF/B grade filters followed by 5 x 1 ml washes with ice cold HEPES (20 mM) /MgCl 2 (3 mM) buffer. Radioactivity is measured using liquid scintillation spectrometry. This procedure is hereafter referred to as the [35s]GTP ⁇ S functional assay.
  • the compounds of formula (I) show high affinity for the 5W ⁇ A_, 5-HTI g and 5-HTID receptors. It has been found, using the [ 3 ⁇ S]GTP ⁇ S functional assay, that certain compounds of formula (I) appear to be antagonists whilst others appear to be agonists, partial agonists or inverse agonists. The difficulties in describing intrinsic activity of drugs acting at G protein coupled receptors is recognised in the art (Hoyer and Boddeke, Trends in Pharmocological Sciences, July 1993, [Vol. 14], page 270-275). We believe that however these ligands are classified according to this functional assay, the compounds of this invention will be useful antidepressants in vivo.
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, a selective serotonin reuptake inhibitor (SSRI) antidepressant.
  • SSRI selective serotonin reuptake inhibitor
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred. Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents The tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • the following Examples illustrate the preparation of compounds of the invention.
  • the mixture was then concentrated in vacuo to a gum, which was partitioned between 2M sodium hydroxide solution and dichloromethane.
  • the aqueous layer was separated, adjusted to pH 0 with 6M hydrochloric acid and washed with dichloromethane; then adjusted to pH 7 by addition of aqueous potassium carbonate solution and extracted with dichloromethane.
  • the dichloromethane extract was dried (Na 2 SO4) an ⁇ ⁇ concentrated in vacuo to give the title compound, which crystallised from ether as needles mp 210-215°C (465mg, 46%).
  • reaction mixture was cooled and concentrated in vacuo to approx 150 ml volume, then acidified with 2M HC1 acid (200 ml) and shaken well with ethyl acetate (400 ml).
  • the solid present was filtered off, shaken with 10% Na 2 CO3 solution and dichloromethane, and the organic layer separated, dried (Na 2 SO_ ⁇ ) and concentrated in vacuo to afford the title compound as an orange/yellow solid (2.3g, 56%).
  • the title compound was prepared in a similar manner to Example 1 from 2,3-dichloro-4- (pyridin-4-yl)aniline (D9, 0.20g, 0.85 mmole), 5-amino-3-(l-methylpiperidin-4-yl)-lH- indole (D2, 0.15g, 0.66 mmole), triphosgene (O.lOg, 0.34 mmole) and triethylamine (0.30ml). This was obtained as a pink white solid (0.18g).
  • Example 5 N-[3-(l-Methylpiperidin-4-yl)indol-5-yI]-4-(pyridin-4-yl)naphth-l-ylacetamide (E5)
  • a stirred suspension of 4-(pyridin-4-yl)naphth-l-ylacetic acid (D7, 0.18g, 0.7 mmole) in dichloromethane (15ml) was treated with oxalyl chloride (0.18ml, 2.1 mmole), then stirred at room temperature for 3hours, before evaporating to dryness.
  • the title compound was prepared in a similar manner to Example 1 from 4-(pyridin-4- yl)naphth-l -ylamine (D3, 0.16g, 0.7 mmole), 7-(l-methylpiperidin-4-yl)-l,2,3,5- tetrahydropyrrolo[2,3-fJindole (D6, 0.15g, 0.6 mmole), triphosgene (0.08g, 0.28 mmole) and triethylamine (0.25ml). This was obtained as a cream powder (0.1 lg).
  • the title compound was prepared in a similar manner to Example 1 from 3-chloro-4- (pyridin-4-yl)aniline (prepared using a similar procedure to Description 11) (0.18g, 0.88 mmole), 5-amino-3-(l-methylpiperidin-4-yl)-lH-indole (D2, 0.15g, 0.66 mmole), triphosgene (O.lOg, 0.34 mmole) and triethylamine (0.3ml). This was obtained as a off- white powder.
  • Example 1 as a white solid (41%).
  • Examples 1, 3, 4, 8, 9, 10 and 12 had pKi values >8.0 at 5-HTi A, 5-HTIB and 5-HT 1D receptors.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I) qui sont des ligands pour 5-HT1, leurs procédés de préparation, des compositions les renfermant et leur utilisation dans le traitement de troubles du SNC.
EP98946322A 1997-08-09 1998-08-06 Composes bicycliques servant de ligands pour les recepteurs 5-ht1 Expired - Lifetime EP1003738B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9716804.1A GB9716804D0 (en) 1997-08-09 1997-08-09 Novel compounds
GB9716804 1997-08-09
GBGB9801633.0A GB9801633D0 (en) 1998-01-26 1998-01-26 Novel compounds
GB9801633 1998-01-26
PCT/EP1998/005116 WO1999007700A1 (fr) 1997-08-09 1998-08-06 Composes bicycliques servant de ligands pour les recepteurs 5-ht1

Publications (2)

Publication Number Publication Date
EP1003738A1 true EP1003738A1 (fr) 2000-05-31
EP1003738B1 EP1003738B1 (fr) 2003-11-19

Family

ID=26312033

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946322A Expired - Lifetime EP1003738B1 (fr) 1997-08-09 1998-08-06 Composes bicycliques servant de ligands pour les recepteurs 5-ht1

Country Status (6)

Country Link
US (1) US6391891B1 (fr)
EP (1) EP1003738B1 (fr)
JP (1) JP2001512727A (fr)
CA (1) CA2299286A1 (fr)
DE (1) DE69819903T2 (fr)
WO (1) WO1999007700A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031086A1 (fr) * 1997-12-12 1999-06-24 Smithkline Beecham Plc Derives de quinoleinepiperazine et de quinoleinepiperidine, leur preparation et leur utilisation en tant qu'antagonistes combines des recepteurs 5-ht1a, 5-ht1b et 5-ht1d
WO2000055139A2 (fr) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'agents anti-inflammatoires
US6492393B1 (en) * 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2001087878A1 (fr) * 2000-05-18 2001-11-22 Daiichi Pharmaceutical Co., Ltd. Nouveaux dérivés de benzothiophène
WO2003032989A1 (fr) * 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. Composes d'uree benzo fusionnes 1,4-disubstitues utilises comme inhibiteurs des cytokines
EP1608319A4 (fr) 2003-04-03 2007-02-28 Univ California Inhibiteurs ameliores pour hydrolase epoxyde soluble
EP1765311A4 (fr) 2004-03-16 2009-04-29 Univ California Reduction de la nephropathie au moyen d'inhibiteurs d'hydrolase d'epoxyde soluble et d'epoxyeicosanoides
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
CN102083794A (zh) * 2008-05-05 2011-06-01 安姆根有限公司 作为γ分泌酶调节剂的脲化合物
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RS57618B1 (sr) * 2013-08-02 2018-11-30 Pfizer Heterobicikloaril rorc2 inhibitori i postupci za njihovu upotrebu
WO2016120849A1 (fr) 2015-01-30 2016-08-04 Pfizer Inc. Modulateurs de pyrrolopyridine substituée par un méthoxy de rorc2 et leurs méthodes d'utilisation
EP3250561A1 (fr) 2015-01-30 2017-12-06 Pfizer Inc Modulateurs indole de rorc2 substitués par sulfonamide et leurs procédés d'utilisation
WO2017152117A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
WO2022030589A1 (fr) * 2020-08-05 2022-02-10 国立大学法人北海道大学 Ligand contenant un composé de coordination monodenté d'urée et catalyseur de borylation le contenant
MX2023009682A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
WO2022175752A1 (fr) 2021-02-19 2022-08-25 Sudo Biosciences Limited Inhibiteurs de tyk2 et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
UA41297C2 (uk) * 1991-11-25 2001-09-17 Пфайзер, Інк. Похідні індолу, фармацевтична композиція і спосіб лікування
IL106445A (en) 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
WO1995006044A1 (fr) * 1993-08-20 1995-03-02 Smithkline Beecham Plc Derives d'amide et d'uree en tant qu'antagonistes du recepteur 5ht1d
EP0716649B1 (fr) 1993-08-31 1998-09-09 Pfizer Inc. Derives de 5-arylindole
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
GB2289465A (en) 1994-05-19 1995-11-22 Merck Sharp & Dohme Five-membered heteroaromatic 5-HT receptor agonists
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9907700A1 *

Also Published As

Publication number Publication date
DE69819903D1 (de) 2003-12-24
WO1999007700A1 (fr) 1999-02-18
EP1003738B1 (fr) 2003-11-19
DE69819903T2 (de) 2004-11-11
JP2001512727A (ja) 2001-08-28
US6391891B1 (en) 2002-05-21
CA2299286A1 (fr) 1999-02-18

Similar Documents

Publication Publication Date Title
EP1003738B1 (fr) Composes bicycliques servant de ligands pour les recepteurs 5-ht1
US6159979A (en) Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
CA2355234A1 (fr) Composes
AU684276B2 (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
US5756496A (en) Amide derivatives having 5HT1D-antagonist activity
WO1998047868A1 (fr) Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
WO1996011929A1 (fr) Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
WO1998050346A2 (fr) Derives d'acetamide et d'uree, procede de preparation et utilisation de ces derives dans le traitement des troubles du systeme nerveux central
JP2005507875A (ja) カンナビノイド受容体に作用する新規なピラゾール類似体
EP1047691A1 (fr) Derives de quinoleinepiperazine et de quinoleinepiperidine, leur preparation et leur utilisation en tant qu'antagonistes combines des recepteurs 5-ht1a, 5-ht1b et 5-ht1d
AU675880B2 (en) 1(2H-1-benzopyran-2-one-8-yl)-piperazine derivatives
EP1228043B1 (fr) Derives d'isoquinoline et de quinazoline dotes d'une activite combinee de recepteur 5ht1a, 5ht1b et 5ht1d
DK163990B (da) Oxindol-3-carboxamid-derivater og farmaceutiske praeparater indeholdende disse
JP2003503483A (ja) ジヒドロベンゾジアゼピンおよび異脂肪血症におけるそれらの使用
JPH07505394A (ja) 橋渡しビスアリールカルビノール誘導体，組成物および使用法
WO2000006575A2 (fr) Nouveaux composes
KR101082227B1 (ko) 피라졸로피리미딘 화합물의 메탄술폰산염, 그 결정 및 그제조 방법
WO2001032659A1 (fr) Derives d'isoquinoline et de quinazoline destines au traitement des troubles du snc
WO1999029666A1 (fr) Derives d'arylpiperazine et d'arylpiperidine, leur mise au point et leur utilisation en tant qu'antagonistes des recepteurs de 5-ht1a, 5-ht1b et 5-ht1d combines
JPH09508637A (ja) ５ｈｔ２ｂレセプタ拮抗薬縮合インドール
US6166034A (en) Spiro piperidine derivatives as 5HT1D receptor antagonists
KR20010052526A (ko) 5-ｈｔ 수용체에 대해 친화성이 있는ｎ-벤조디옥사닐메틸-1-피페리딜-메틸아민 화합물
EP1226120B1 (fr) Utilisation de benz[f]indoles dans le traitement de troubles dus au recepteur 5ht
MXPA01006243A (en) Compounds
EP0889892A1 (fr) Derives azaspiro

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20020312

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE ES FR GB IT LI NL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031119

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031119

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20031119

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031119

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031119

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69819903

Country of ref document: DE

Date of ref document: 20031224

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040302

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040806

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050429

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST